
Vol. 27, No. 3, 1981
Free Abstract
Article (PDF 3580 KB)
Original Paper
Suppression of Secondary Hyperparathyroidism by Propranolol in Renal Failure Patients
Anatole Besarab, Jose F. Caro, Benno U. Ihle, James F. Burke, Jr., Joseph.A. Glennon, Jan A. Fischer
Department of Medicine (Divisions of Nephrology and Endocrinology), Thomas Jefferson University Hospital, Philadelphia, Pa., USA and Orthopedic Clinic and Department of Internal Medicine, University of Zurich, Zurich, Switzerland
Address of Corresponding Author
Nephron 1981;27:127-133 (DOI: 10.1159/000182038)
Key Words
- Renal osteodystrophy
- Secondary hyperparathyroidism
- Propranolol
Abstract
Renal osteodystrophy, in part due to secondary hyperparathyroidism, is one of the major unresolved problems affecting patients on chronic hemodialysis. In addition, evidence has shown that parathyroid hormone (PTH) is toxic to other organ systems besides bone. The results of a prospective study on the effect of propranolol in reducing PTH levels in chronic renal failure patients on hemodialysis are reported. Propranolol administration reduced PTH levels by over 50-75%. The levels of calcium, phosphorus, alkaline phosphatase and hematocrit were variable, but patients with severe derangements in these measurements also seemed to benefit from propranolol. It should now be determined by larger and longer studies whether these biochemical improvements can be translated into clinical benefits. Copyright © 1981 S. Karger AG, Basel
Author Contacts Anatole Besarab, MD, Division of Nephrology, Room 1016, Jefferson Medical College, 1025 Walnut Street, Philadelphia, PA 19107 (USA)
Article Information
Accepted: June 4, 1980
Published online: December 02, 2008
Number of Print Pages : 7
|
|

|

For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service. |
|
|